Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serpin family B member 13 (SERPINB13)
- Target
- SERPINB13
- Molecular classification
- Protease inhibitor, Serine proteinase inhibitor, Cysteine proteinase inhibitor, Serpin (serine protease inhibitor) superfamily, clade B (ovalbumin)
01
Overview
Serpin family B member 13 (SERPINB13) is a protein-coding gene and member of the serpin superfamily, notable for inhibiting serine and cysteine proteases such as cathepsin K and cathepsin L. In humans, it plays a role in keratinocyte proliferation and differentiation and is transcriptionally repressed by the transcription factor RUNX1. It is downregulated in several cancers, including squamous cell carcinoma and has been implicated in inflammatory skin disorders such as psoriasis. SERPINB13 regulates the Notch signaling pathway in pancreatic development, with studies suggesting therapeutic potential in diabetes by modulating β cell mass through immune targeting. It may act as a biomarker for cancer or diabetes progression via its expression or antibody response.
- Other names
- Serpin B13PI13HurpinHeadpinPeptidase inhibitor 13Proteinase inhibitor 13HUR7HaCaT UV-repressible serpinUV-B repressed sequenceHSHUR7SEQHURPINSERPINB13
02
Mechanism of action
Protease inhibition (specifically inhibiting cathepsin K and cathepsin L). Potentially promoting β cell development via blockade by antibody (facilitating pancreatic progenitor conversion). Modulation of Notch signaling via protease inhibition.
03
Biological functions
Inhibition of cathepsin KInhibition of cathepsin LRegulation of keratinocyte proliferation or differentiationModulation of Notch signaling (developmental pathway)Peptidase inhibition (general)
04
Disease associations
Cancer (downregulated in many types, including squamous cell carcinoma, head and neck)PsoriasisDiabetes (type 1 diabetes; role in β cell development and islet cell mass)
05
Safety considerations
No widely reported safety concerns specific to direct therapeutic targeting of SERPINB13. Safety aspects would depend on inhibition of its protease targets and possible effects on keratinocyte biology or islet cell development, based on preclinical studies.
06
Interacting drugs
No approved drugs directly targeting SERPINB13 are listed in available sources. Anti-serpinB13 monoclonal antibodies have been studied in research contexts for β cell development and diabetes.
07
Biomarkers
Autoantibodies against serpinB13 can serve as biomarkers for delayed progression to type 1 diabetes in childrenExpression levels of SERPINB13 in tissue may serve as a biomarker for squamous cell carcinoma and other cancer types
Beyond the preview
Go deeper on Serpin family B member 13 (SERPINB13).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serpin family B member 13 (SERPINB13).